CDK4 and neoplasm: Apart from exploring immune checkpoints as tumor biomarkers for predicting disease prognosis, researchers also explored combination therapy based on anti-PD-1 antibodies, such as anti-angiogenesis targeting therapy [66, 67] and CDK4/6 inhibitor [68] which could help improve clinical outcomes.